Alpha 2.0
Login Register
» Authors » Girishanthy Krishnarajah

Girishanthy Krishnarajah

Explore the profile of Girishanthy Krishnarajah including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 44
Citations 527
Followers 0
Related Specialties
Allergy & Immunology
General Medicine
Science
Top 10 Co-Authors
Cristina Masseria
Stephen I Pelton
Mei Sheng Duh
Victoria Divino
Bhakti Arondekar
Mitch DeKoven
Songkai Yan
Patrick Lefebvre
Joaquin Mould-Quevedo
Maarten J Postma
Published In
Hum Vaccin Immunother
Vaccine
PLoS One
Curr Med Res Opin
BMC Infect Dis
Affiliations
Soon will be listed here.
Recent Articles
1.
Economic burden of invasive disease among older adult patients treated in hospitals in the United States
Hernandez-Pastor L, Geurtsen J, Baugh B, El Khoury A, Kalu N, Krishnarajah G, et al.
J Manag Care Spec Pharm . 2023 Jul; 29(8):873-883. PMID: 37523312
Although invasive disease (IED) can lead to severe clinical outcomes, little is known about the associated medical resource use and cost burden of IED in US hospitals. To comprehensively describe...
2.
Respiratory Syncytial Virus-Related Complications and Healthcare Costs Among a Medicare-Insured Population in the United States
DeMartino J, Lafeuille M, Emond B, Rossi C, Wang J, Liu S, et al.
Open Forum Infect Dis . 2023 May; 10(5):ofad203. PMID: 37213421
Background: Literature describing respiratory syncytial virus (RSV)-related complications in older adults in the United States is scarce. This study described risk factors of RSV-related complications and healthcare costs of Medicare-insured...
3.
A retrospective cohort study assessing relative effectiveness of adjuvanted versus high-dose trivalent influenza vaccines among older adults in the United States during the 2018-19 influenza season
Pelton S, Divino V, Postma M, Shah D, Mould-Quevedo J, DeKoven M, et al.
Vaccine . 2021 Apr; 39(17):2396-2407. PMID: 33810903
Purpose: To evaluate the relative vaccine effectiveness (rVE) against influenza-related hospitalizations/emergency room (ER) visits, influenza-related office visits, and cardio-respiratory disease (CRD)-related hospitalizations/ER visits and compare all-cause and influenza-related costs associated...
4.
Clinical and Economic Outcomes Associated with Cell-Based Quadrivalent Influenza Vaccine vs. Standard-Dose Egg-Based Quadrivalent Influenza Vaccines during the 2018-19 Influenza Season in the United States
Krishnarajah G, Divino V, Postma M, Pelton S, Anupindi V, DeKoven M, et al.
Vaccines (Basel) . 2021 Jan; 9(2). PMID: 33498724
Non-egg-based influenza vaccines eliminate the potential for egg-adapted mutations and potentially increase vaccine effectiveness. This retrospective study compared hospitalizations/emergency room (ER) visits and all-cause annualized healthcare costs among subjects aged...
5.
Evaluating the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to High-Dose Trivalent and Other Egg-Based Influenza Vaccines among Older Adults in the US during the 2017-2018 Influenza Season
Pelton S, Divino V, Shah D, Mould-Quevedo J, DeKoven M, Krishnarajah G, et al.
Vaccines (Basel) . 2020 Aug; 8(3). PMID: 32784684
The influenza-related disease burden is highest among the elderly. We evaluated the relative vaccine effectiveness (rVE) of adjuvanted trivalent influenza vaccine (aTIV) compared to other egg-based influenza vaccines (high-dose trivalent...
6.
A real-world study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017-18 influenza season
Divino V, Krishnarajah G, Pelton S, Mould-Quevedo J, Anupindi V, DeKoven M, et al.
Vaccine . 2020 Aug; 38(40):6334-6343. PMID: 32739119
Background: Cell-based influenza vaccine manufacturing reduces egg adaptations that can decrease vaccine effectiveness. We evaluated the relative vaccine effectiveness (rVE) of cell-based quadrivalent influenza vaccine (QIVc) compared to standard-dose egg-based...
7.
Co-occurrence between C1 esterase inhibitor deficiency and autoimmune disease: a systematic literature review
Levy D, Craig T, Keith P, Krishnarajah G, Beckerman R, Prusty S
Allergy Asthma Clin Immunol . 2020 Jun; 16:41. PMID: 32514272
Background: Hereditary angioedema (HAE) is caused by a SERPING1 gene defect resulting in decreased (Type I) or dysfunctional (Type II) C1 esterase inhibitor (C1-INH). The prevalence of autoimmune diseases (ADs)...
8.
Assessing bleeding rates, related clinical impact and factor utilization in German hemophilia B patients treated with extended half-life rIX-FP compared to prior drug therapy
Oldenburg J, Yan S, Maro G, Krishnarajah G, Tiede A
Curr Med Res Opin . 2019 Aug; 36(1):9-15. PMID: 31469321
An extended half-life factor IX (FIX) fusion protein linking recombinant FIX with recombinant human albumin (rIX-FP), indicated for the treatment of hemophilia B, was approved by the European Medicines Agency...
9.
Indirect comparison of intravenous vs. subcutaneous C1-inhibitor placebo-controlled trials for routine prevention of hereditary angioedema attacks
Bernstein J, Li H, Craig T, Manning M, Lawo J, Machnig T, et al.
Allergy Asthma Clin Immunol . 2019 Mar; 15:13. PMID: 30899278
Introduction: For prophylaxis of hereditary angioedema (HAE) attacks, replacement therapy with human C1-inhibitor (C1-INH) treatment is approved and available as intravenous [C1-INH(IV)] (Cinryze) and subcutaneous [C1-INH(SC)] HAEGARDA preparations. In the...
10.
The economic burden of CIDP in the United States: A case-control study
Divino V, Mallick R, DeKoven M, Krishnarajah G
PLoS One . 2018 Oct; 13(10):e0206205. PMID: 30352101
Background: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder of the peripheral nervous system. The economic burden of CIDP is not well understood. Objectives: To assess the economic...